These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1196872)

  • 21. [Clinical aspects and pathogenesis of the "on-off" phenomenon in Parkinson syndrome].
    Jörg J; Schneider I
    Fortschr Neurol Psychiatr; 1988 Jan; 56(1):22-34. PubMed ID: 3126121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benign tremulous parkinsonism.
    Josephs KA; Matsumoto JY; Ahlskog JE
    Arch Neurol; 2006 Mar; 63(3):354-7. PubMed ID: 16533962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.
    Schrag A; Ben-Shlomo Y; Brown R; Marsden CD; Quinn N
    Mov Disord; 1998 Nov; 13(6):885-94. PubMed ID: 9827611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P; Bathien N; Dumas JL
    Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
    [No Abstract]   [Full Text] [Related]  

  • 26. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Gasser T; Arnold G; Pogarell O; Künig G; Oertel WH
    Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Problems in the administration of L-DOPA (author's transl)].
    Ferrari E
    Riv Patol Nerv Ment; 1974 Aug; 95(4):239-50. PubMed ID: 4283417
    [No Abstract]   [Full Text] [Related]  

  • 28. [An autopsy case of progressive supranuclear palsy showing "pure akinesia without rigidity and tremor and with no effect by L-dopa therapy (Imai)"].
    Homma Y; Takahashi H; Takeda S; Ikuta F
    No To Shinkei; 1987 Feb; 39(2):183-7. PubMed ID: 3828155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Juvenile parkinsonism. 18 cases].
    Ferreiro JL; Pugliese MI; Caride AE
    Medicina (B Aires); 1991; 51(3):204-8. PubMed ID: 1821902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies?
    Ransmayr G; Künig G; Neubauer M; Wagner M; Bösch S; Kreczy-Kleedorfer B
    Adv Neurol; 1993; 60():685-9. PubMed ID: 8420211
    [No Abstract]   [Full Text] [Related]  

  • 31. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Development of Parkinson's disease].
    Guillard A
    Rev Prat; 1989 Mar; 39(8):653-7. PubMed ID: 2727572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
    Albani C; Buck A
    Adv Neurol; 1993; 60():386-9. PubMed ID: 8420158
    [No Abstract]   [Full Text] [Related]  

  • 35. Sudden confusion with levodopa withdrawal.
    Lang AE
    Mov Disord; 1987; 2(3):223. PubMed ID: 3504551
    [No Abstract]   [Full Text] [Related]  

  • 36. [Dystonia preceding dopa-responsive parkinsonism--heterogeneous clinical features].
    Miwa H; Mizuno Y
    No To Shinkei; 1996 Feb; 48(2):149-54. PubMed ID: 8865694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of dihydroergotamine in the prevention and treatment of orthostatic hypotension syndromes in patients with parkinsonism treated with L-dopa].
    Jubert Gruart J; Balcells Riba M
    Arch Neurobiol (Madr); 1974; 37(4):401-12. PubMed ID: 4433212
    [No Abstract]   [Full Text] [Related]  

  • 38. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of advanced Parkinson's disease.
    Diamond A; Jankovic J
    Expert Rev Neurother; 2006 Aug; 6(8):1181-97. PubMed ID: 16893346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.